TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03430609

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic treatment for endometrioma Astus©
Description: Laparoscopic surgery will be performed by the same surgeon, according to the routine of the service.In all of the groups, endometrioma will be removed by means of the traction and countertraction techniques. Adhesiolysis will be performed to separate the ovary from the adjacent structures as needed. In case of cyst rupture, the contents will be aspirated, and the site where the endometrioma contents fell will be exhaustively rinsed. In the hemostasis , the investigators will use coagulation with bipolar tweezers Astus Medical© in this group.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: AMH Level
Description: The AMH levels will be quantitatively measured via ELISA, Enzyme-Linked Immunosorbent Assay (Diagnostic Systems Laboratories, Webster, TX), with a detection sensitivity of 0.006 ng/mL.~The participants' sera will be obtained from blood samples after centrifugation for 10 minutes to separate the cell contents and debris. Each serum sample will be transferred to polypropylene tubes and stored at -70ºC. Venous blood samples will be collected before surgery (on the day ultrasound is performed for antral follicle count, approximately 1 month before surgery) and 1, 3 and 6 months after surgery.
Study: NCT02861729

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vita Suprinity
Description: zirconia reinforced lithium silicate partial coverage restorations

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: IPS e.max
Description: lithium disilicate partial coverage restorations
Study: NCT02475161

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-42847922
Description: JNJ-42847922 will be administered as 20 mg tablet orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole
Description: Rabeprazole will be administered as 20 mg tablet orally.
Study: NCT00888472

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Leukocytapheresis
Description: 5000 ml, the blood volume per body, treated once. Twice at an interval of 6 days.
Study: NCT01301378

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Molteno 3 glaucoma drainage shunt
Description: Patients needing glaucoma drainage surgery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Molteno 3 glaucoma drainage shunt
Description: Patients needing glaucoma drainage surgery
Study: NCT00960687

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fenofibric Acid (Fibricor™) 105 mg Tablet
Description: 1 x 105 mg fenofibric acid (Fibricor™) tablet administered 30 minutes after the initiation of a standard breakfast.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fenofibrate (Tricor®) 145 mg Tablet
Description: 1 x 145 mg Fenofibrate (Tricor®) tablet administered 30 minutes after the start of a standard breakfast.
Study: NCT01615757

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ara-c
Description: IV formulation, administered as a 2 hr infusion in 1 pint of normal saline, BD on D1,3,5 at 3 gm/m2 /dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ara-c
Description: IV formulation, administered as a 2 hr infusion in 1 pint of normal saline, BD on D1,3,5 at 2 gm/m2 /dose
Study: NCT00929201

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin phosphate/metformin hydrochloride FDC
Description: Single dose sitagliptin/metformin 50/500 mg FDC tablet after consumption of a high-fat meal in one of two treatment periods.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin phosphate/metformin hydrochloride FDC
Description: Single dose sitagliptin/metformin 50/500 mg FDC tablet after consumption of a high-fat meal in one of two treatment periods.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin phosphate
Description: Single dose sitagliptin 50 mg tablet after consumption of a high-fat meal in one of two treatment periods.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin phosphate
Description: Single dose sitagliptin 50 mg tablet after consumption of a high-fat meal in one of two treatment periods.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin hydrochloride
Description: Single dose metformin 500 mg tablet after consumption of a high-fat meal in one of two treatment periods.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin hydrochloride
Description: Single dose metformin 500 mg tablet after consumption of a high-fat meal in one of two treatment periods.
Study: NCT03256526

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06835919 Low Dose
Description: 75 mg once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06835919 High Dose
Description: 300 mg once daily
Study: NCT03430609

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: AMH Level
Description: The AMH levels will be quantitatively measured via ELISA, Enzyme-Linked Immunosorbent Assay (Diagnostic Systems Laboratories, Webster, TX), with a detection sensitivity of 0.006 ng/mL.~The participants' sera will be obtained from blood samples after centrifugation for 10 minutes to separate the cell contents and debris. Each serum sample will be transferred to polypropylene tubes and stored at -70ºC. Venous blood samples will be collected before surgery (on the day ultrasound is performed for antral follicle count, approximately 1 month before surgery) and 1, 3 and 6 months after surgery.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: AMH Level
Description: The AMH levels will be quantitatively measured via ELISA, Enzyme-Linked Immunosorbent Assay (Diagnostic Systems Laboratories, Webster, TX), with a detection sensitivity of 0.006 ng/mL.~The participants' sera will be obtained from blood samples after centrifugation for 10 minutes to separate the cell contents and debris. Each serum sample will be transferred to polypropylene tubes and stored at -70ºC. Venous blood samples will be collected before surgery (on the day ultrasound is performed for antral follicle count, approximately 1 month before surgery) and 1, 3 and 6 months after surgery.
Study: NCT03971032

Intervention type: DEVICE
Group type: OTHER
Intervention: Infrared Spectroscopy
Description: This device uses spectral absorption of the tissue taken during hysteroscopy to determine immediate diagnosis of malignancy
Study: NCT00958828

Intervention type: DEVICE
Group type: OTHER
Intervention: Nelfilcon A contact lens
Description: Spherical, soft contact lens for daily disposable wear

Intervention type: DEVICE
Group type: OTHER
Intervention: Nelfilcon A contact lens
Description: Spherical, soft contact lens for daily disposable wear

Intervention type: DEVICE
Group type: OTHER
Intervention: Narafilcon A contact lens
Description: Spherical, soft contact lens for daily disposable wear
Study: NCT02024386

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riociguat
Description: After completion of first V02 max test at altitude, subjects will have a 3-hour rest period. Riociguat will be administered at the 90-minute mark of this rest period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riociguat
Description: After completion of first V02 max test at altitude, subjects will have a 3-hour rest period. Riociguat will be administered at the 90-minute mark of this rest period.
Study: NCT04338646

Intervention type: OTHER
Intervention: Clinical tests
Description: Questionnaire about urinary symptoms, gait difficulties, fear of falling. Clinical test: Time to be Ready to Void
Study: NCT03107416

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hepatic artery embolization (HAE)
Description: The intervention being studied is HAE for the treatment of HCC in combination with Bumetanide. HAE is a standard of care procedure.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bumetanide
Description: Intra-arterial (IA) injection of 0.01mg/kg of Bumetanide in the first cohort, 0.02 mg/kg in the second cohort and 0.04 mg/kg of IA Bumetanide in the final cohort patients during standard HAE until stasis is evident.
Study: NCT03586986

Intervention type: DIAGNOSTIC_TEST
Intervention: Brain MRI
Description: Perform brain MRI; draw blood; fill out bioscreen questionnaire; perform SDMT

Intervention type: DIAGNOSTIC_TEST
Intervention: Brain MRI
Description: Perform brain MRI; draw blood; fill out bioscreen questionnaire; perform SDMT
Study: NCT01966107

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aclidinium Bromide
Description: 400 μg, twice per day, oral administration via a multi-dose dry-powder inhaler (DPI)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dose matched placebo, twice per day, oral administration via a multi-dose dry-powder inhaler (DPI)
Study: NCT02856282

Intervention type: DRUG
Intervention: Pirinase Hayfever Relief for Adults 0.05% Nasal Spray
Description: Aqueous suspension of 0.05% micronised fluticasone propionate.Each actuation contains 50 micrograms of fluticasone propionate
Study: NCT03300882

Intervention type: OTHER
Intervention: Procedure
Description: Serial blood draws. Participants will be enrolled either pre-transplant or within 45 days post-transplant and will be followed over the course of 18 months post transplant. Protocol mandated serial measurement of cytomegalovirus (CMV)-specific immune signature will occur pre-transplant (as applicable) and at post-transplant timepoint months 2, -3, -6, -9, -12 and -18.
Study: NCT00958828

Intervention type: DEVICE
Group type: OTHER
Intervention: Narafilcon A contact lens
Description: Spherical, soft contact lens for daily disposable wear
Study: NCT03285347

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Computer-based cognitive training
Description: Computer-based cognitive programmes are computer programmes designed as games with the aim of training patients in certain cognitive domains.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Computer-based cognitive training
Description: Computer-based cognitive programmes are computer programmes designed as games with the aim of training patients in certain cognitive domains.
Study: NCT02863796

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WhiteSwell System
Description: To promote movement of interstitial fluid to the intravascular space to allow for the body to remove it, in conjunction with a diuresis regimen.
Study: NCT03268083

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EV71 vaccine ([0.5 μg total protein + adjuvant 150 μg AI(OH)3] per dose)
Description: Two vaccinations at 28 days apart

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EV71 vaccine ([0.5 μg total protein + adjuvant 150 μg AI(OH)3] per dose)
Description: Two vaccinations at 28 days apart
Study: NCT01495962

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum Toxin Type A
Description: Six 25 cc injection of Botulinum Toxin A

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (Normal Saline)
Study: NCT03268083

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EV71 vaccine ([1 μg total protein + adjuvant 150 μg AI(OH)3] per dose)
Description: Two vaccinations at 28 days apart

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EV71 vaccine ([1 μg total protein + adjuvant 150 μg AI(OH)3] per dose)
Description: Two vaccinations at 28 days apart

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EV71 vaccine ([1 μg total protein ] per dose)
Description: Two vaccinations at 28 days apart

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EV71 vaccine ([1 μg total protein ] per dose)
Description: Two vaccinations at 28 days apart
Study: NCT03765489

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: electrical muscle stimulation
Description: electrical muscle stimulation: The parameters used in biceps were: 35 Hz, 250 μs and in quadriceps were: 50 Hz, 400 μs. In both, biphasic wave was used, 45 minutes of total work, 5 seconds of contraction and 10 seconds of relaxation and the intensity was adjusted to present a visible contraction

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional physical therapy
Description: conventional physical therapy according to the adaptation of the Start to move protocol of Gosselink et al

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional physical therapy
Description: conventional physical therapy according to the adaptation of the Start to move protocol of Gosselink et al
Study: NCT03359148

Intervention type: DEVICE
Intervention: Disposable ventilator system

Intervention type: DEVICE
Intervention: Conventional reused ventilator system
Study: NCT04456777

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vortioxetine
Description: vortioxetine will be administreted for 3 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vortioxetine
Description: vortioxetine will be administreted for 3 months
Study: NCT00837837

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorpheniramine
Study: NCT02673177

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: robot-assisted total mesorectal excision
Description: The Da Vinci Surgical System may help to protect subtle anatomical structure and provide more functional protection when compared to laparoscopic surgery. This study aimed to compare RTME and laparoscopic total mesorectal excision (LTME) for rectal cancer with regard to Urinary, sexual function and sphincter- preservation outcomes.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopic total mesorectal excision
Description: Traditional laparoscopic total mesorectal excision (LTME) for rectal cancer.
Study: NCT02437773

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy - Adolescents
Description: A therapy which gradually yet repeatedly exposes adolescent patients to their obsessive compulsive-relevant error cues during a task performance until their anxiety habituates.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Stress Management Therapy - Adolescents
Description: An active control therapy with minimal effects on OCD symptoms.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Optional CBT - Adolescents
Description: This is the cross-over element for those that completed the SMT treatment group and opt to have the OCD treatment.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Optional CBT - Adolescents
Description: This is the cross-over element for those that completed the SMT treatment group and opt to have the OCD treatment.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy - Adults
Description: A therapy which gradually yet repeatedly exposes adult patients to their obsessive compulsive-relevant error cues during a task performance until their anxiety habituates.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Stress Management Therapy - Adults
Description: An active control therapy with minimal effects on OCD symptoms.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Optional CBT - Adults
Description: This is the cross-over element for those that completed the SMT treatment group and opt to have the OCD treatment.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Optional CBT - Adults
Description: This is the cross-over element for those that completed the SMT treatment group and opt to have the OCD treatment.

Intervention type: OTHER
Group type: OTHER
Intervention: fMRI only - Healthy Control Adults
Description: Two fMRI's only, scheduled at 12-weeks apart. This is for Healthy Control Adults and is used only as a means for observation, NOT as an intervention to be studied.

Intervention type: OTHER
Group type: OTHER
Intervention: fMRI only - Healthy Control Adolescents
Description: Two fMRI's only, scheduled at 12-weeks apart. This is for Healthy Control Adolescents and is used only as a means for observation, NOT as an intervention to be studied.
Study: NCT00799890

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunphenon EGCG
Description: 200-800mg (1-4 capsules)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1-4 capsules
Study: NCT01240759

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-707106 Dose A
Description: One S-707106 A tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-707106 Dose B
Description: One S-707106 B tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-707106 Dose C
Description: Four S-707106 4 X B tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo A tablet
Description: Up to 4 Placebo A tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo A tablet
Description: Up to 4 Placebo A tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo A tablet
Description: Up to 4 Placebo A tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: The standard of care dose of metformin for each patient

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: The standard of care dose of metformin for each patient

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: The standard of care dose of metformin for each patient

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: The standard of care dose of metformin for each patient
Study: NCT01004354

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ergocalciferols
Description: 2000 international units by mouth daily for 8 weeks.
Study: NCT01198470

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TRIUMPH® Lumbar Artificial Disc
Description: The TRIUMPH® Lumbar Artificial Disc is an articulating artificial disc inserted using a posterolateral approach to the lumbar spine.
Study: NCT02845024

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxycycline Group
Description: Oral doxycycline 100mg was taken within 15 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo Group
Description: Oral placebo was taken within 15 days
Study: NCT02913911

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: feedback
Description: Sit to stand training with external feedback

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: feedback
Description: Sit to stand training with external feedback
Study: NCT00697463

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teriparatide (PTH 1-34)
Description: 20 micrograms subcutaneous injection daily
Study: NCT02100462

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorthalidone 12.5 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide 25 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin 81 mg
Study: NCT03718988

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meat products
Description: Traditional meat products (beef burger patties, pork sausage, etc.)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meat products
Description: Traditional meat products (beef burger patties, pork sausage, etc.)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Plant Alternative products
Description: Plant-based alternatives (The Beyond Burger, Beyond Sausage, etc.)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Plant Alternative products
Description: Plant-based alternatives (The Beyond Burger, Beyond Sausage, etc.)
Study: NCT03045263

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pivotal Response Treatment
Description: Behavioral intervention for autism
Study: NCT03494712

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S 95010
Description: Single administration of S 95010 in healthy volunteers

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single administration of placebo in healthy volunteers
Study: NCT01268670

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: Subjects will receive topical LET and oral ibuprofen.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone
Description: Subjects will receive topical LET and oral oxycodone.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will receive topical LET and oral placebo.
Study: NCT03857646

Intervention type: DRUG
Group type: OTHER
Intervention: Intralipid, 20% Intravenous Emulsion
Description: Lipids start at 1 g/kg/day and advance by 1 g/kg/day to a maximum of 3 g/kg/day as tolerated by the the neonate.

Intervention type: DRUG
Group type: OTHER
Intervention: SMOF lipid
Description: Lipids start at 1 g/kg/day and advance by 1 g/kg/day to a maximum of 3 g/kg/day as tolerated by the the neonate.
Study: NCT04977011

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: relaxing music
Description: 30 minutes relaxing music for continuity 3 days since admission
Study: NCT02380586

Intervention type: PROCEDURE
Intervention: Obstetric anesthesia and analgesia
Description: All anesthesia procedures during labor: labor analgesia, anesthesia for Cesarean section, anesthesia for procedures in third stage of labor
Study: NCT01076725

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard technique group
Description: In the standard technique group (n = 63), the PLMA was inserted by index finger insertion technique.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rotation technique group
Description: The entire cuff of the PLMA was placed in the mouth without finger insertion in a midline approach and was rotated 90 degrees counterclockwise around the tongue. The PLMA was then advanced and rotated back until resistance was felt.
Study: NCT00534352

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC125; darunavir; ritonavir
Description: TMC125 400mg once daily for 4 weeks; Darunavir-800mg once daily for 48 weeks; Ritonavir-100mg once daily for 48 weeks